Market Currents
UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm...
-
Monday, April 30, 2012, 3:58 PM ETUBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm believes the pullback following the company's disappointing Q1 results is due to transient issues, and the company is still on track for Q2. The firm maintains its buy rating on the shares.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
